35 completed, 6 unknown, 5 recruiting, 3 terminated. 22 Phase 2, 18 Not applicable, 9 Phase 1, 7 Phase 3, 4 Early Phase 1.
Follow epigallocatechin gallate: new trials by email Literature Review of epigallocatechin gallate trials Research Report on epigallocatechin gallate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral or Topical Catechins for Radiation Dermatitis Epicatechin, Epigallocatechin Gallate (EGCG), Microcrystalline Cellulose NF (placebo) - Radiation Dermatitis Acute, Radiation Dermatitis | Phase 3 | Enrolling by invitation | CARLOS FRANCISCO SAAVEDRA GARCIA | 162 | 2026-10-01 | 2026-09-11 |
| Effect of EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid on HPV DNA Integration Epigallocatechin gallate (EGCG), Folic Acid (FA), Vitamin B12 (B12), and Hyaluronic Acid (HA) - HPV Infection, HPV Integration | Not applicable | Not yet recruiting | IRCCS San Raffaele | 42 | 2026-07-01 | 2026-07-13 |
| Effect of a Herbal Intracanal Medication On Postoperative Pain And Flare up Incidence In Non Surgical Root Canal Retreatment Calcium hydroxide, Propolis Extract, Green Tea Polyphenolics (EGCG) - Postoperative Pain, Flare Up, Symptom | Not applicable | Not yet recruiting | Minia University | 40 | 2026-07-01 | 2026-05-11 |
| Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities EGCG and Quinine Sulfate Vaginal Suppository, Placebo - High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion | Phase 2 | Recruiting | Amplexd Therapeutics, Inc. | 45 | 2026-04-30 | 2026-05-14 |
| Reducing Frailty for Older Cancer Survivors Using Supplements II Epigallocatechin-3-Gallate (EGCG), Microcrystalline cellulose (MCC), Ascorbic Acid (Vitamin C) - Frailty, Inflammation | Phase 2 | Suspended | University of Rochester | 118 | 2024-10-25 | 2026-06-26 |
| Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance Curcumin, Epigallocatechin Gallate, Placebo - Mood Disturbance | Early Phase 1 | Recruiting | Auburn University | 64 | 2024-09-30 | 2025-02-14 |
| EGCG for Hepatocellular Carcinoma Chemoprevention Epigallocatechin gallate (EGCG), Placebo - Cirrhosis, Liver | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2024-09-01 | 2025-09-05 |
| The Effect of Natural Molecules on HPV Infection EGCG, FA, HA, B12 - HPV (Human Papillomavirus)-associated | Not applicable | Completed | AGUNCO Obstetrics and Gynecology Centre | 106 | 2024-08-01 | 2025-03-19 |
| A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer Epigallocatechin-3-gallate - Esophageal Cancer, Dysphagia, Esophageal | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 72 | 2024-04-22 | 2024-05-03 |
| Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection Epigallocatechin Gallate - Low-Grade Intraepithelial Neoplasia of Cervix | Unknown | University of Palermo | 50 | 2024-03-01 | 2024-03-15 | |
| The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection. EGCG + folic acid + B12 - HPV Infection | Not applicable | Recruiting | Lo.Li.Pharma s.r.l | 100 | 2024-02-19 | 2025-11-20 |
| Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Hal Chapman | 12 | 2024-02-07 | 2026-04-14 |
| EGCG for the Prevention and Treatment of TIPN Epigallocatechin-3-Gallate, Alcohol - Chemotherapy-induced Peripheral Neuropathy | Phase 1 / Phase 2 | Unknown | Han Xi Zhao | 36 | 2023-11-30 | 2024-07-29 |
| Epigallocatechin Gallate and Other Antural Compounds in HPV Infections EGCG, FA, HA, B12 - Papilloma-induced Cervical Lesions | Phase 2 | Completed | Centro di Ricerca Clinica Salentino | 178 | 2023-11-01 | 2024-07-15 |
| Effect of Epigallocatechin-3-Gallate Solution as a Root Canal Irrigant on Post-Operative Pain Intensity and Bacterial Load Reduction in Necrotic Tooth Epigallocatechin-3-gallate, sodium hypochlorite - Necrotic Pulp | Not applicable | Completed | Cairo University | 40 | 2023-10-01 | 2025-01-10 |
| Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Hal Chapman | 50 | 2023-08-24 | 2026-04-14 |
| Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis Epigallocatechin gallate (EGCG), Sodium hypochlorite (NaOCl), Mineral trioxide aggregate (MTA) - Irreversible Pulpitis | Not applicable | Completed | Cairo University | 64 | 2023-07-01 | 2026-08-24 |
| FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea Green Tea Extract, Placebo - Leiomyoma, Uterine | Phase 3 | Active not recruiting | Yale University | 33 | 2023-01-05 | 2026-08-20 |
| The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism quercetin, EGCG, metformin , zinc - Breast Cancer Female, Triple Negative Breast Cancer | Early Phase 1 | Unknown | Ministry of Health, Saudi Arabia | 200 | 2023-01-01 | 2023-01-11 |
| Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid Epigallocatechin gallate, Vitamin D, Vitamin B6, D-chiro-inositol, Placebo - Uterine Fibroids, D-chiro-inositol | Not applicable | Recruiting | Lo.Li.Pharma s.r.l | 60 | 2022-07-01 | 2026-02-12 |
Showing 20 of 56. Sign in to see all of them.
Multiple Sclerosis (5) · Leiomyoma (4) · Papillomavirus Infections (4) · Idiopathic Pulmonary Fibrosis (3) · Inflammation (3) · Obesity (3) · Alzheimer Disease (2) · Diabetes Mellitus, Type 2 (2) · Down Syndrome (2) · Frailty (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Acne Vulgaris (1) · Amyloidosis (1) · Appetitive Behavior (1) · Atypical Squamous Cells of the Cervix (1)
Charite University, Berlin, Germany (4) · Hal Chapman (3) · Lo.Li.Pharma s.r.l (3) · Parc de Salut Mar (3) · Cairo University (2) · Ministry of Health, Saudi Arabia (2) · Purdue University (2) · Shandong Cancer Hospital and Institute (2) · University of Rochester (2) · Yale University (2) · AGUNCO Obstetrics and Gynecology Centre (1) · Amplexd Therapeutics, Inc. (1) · Auburn University (1) · Baylor College of Medicine (1) · CARLOS FRANCISCO SAAVEDRA GARCIA (1)
United States (18) · Italy (8) · Germany (7) · Spain (4) · China (3) · Egypt (2) · Brazil (1) · Denmark (1) · Hong Kong (1) · Israel (1) · Mexico (1) · Netherlands (1) · South Korea (1) · Taiwan (1)
Friedemann Paul, Dr. (2) · Andrea Etrusco, M.D. (1) · Andrew D Fruge, PhD (1) · Arne Astrup, Proffessor (1) · Ayman Al-Hendy, MD, PhD (1) · Ayman Al-Hendy, MD,PhD (1) · Benedetto Falsini, MD (1) · Bruce R Hamaker, PhD (1) · Carl L Keen, PhD (1) · Carmen Palacios, MD; PhD; MMSc; genetics (1) · Cesare Aragona, MD (1) · Cordelia Running, PhD (1) · Dae Hun Suh, M.D., Ph.D. (1) · Dario Marangoni, M.D. (1)
PMID 32160670, PMID 40077973, PMID 19290537, PMID 19542190, PMID 25733633, PMID 26298797, PMID 27302362, PMID 27320846, PMID 31278067, PMID 33472968, PMID 33622766, PMID 33762428, PMID 33995239, PMID 34655570, PMID 37116909, PMID 38216200, PMID 41484421, PMID 42833136
R01HD100369 (2), K23AT004433 (1), R01HL142265 (1), R21AT003892 (1), R21AT004673 (1), R33HL158540 (1)